XLO

Xilio Therapeutics, Inc. XLO

XLO
Xilio Therapeutics, Inc. PDSB
PDS Biotechnology Corporation ATNM
Actinium Pharmaceuticals, Inc. TPST
Tempest Therapeutics, Inc. OKUR
OnKure Therapeutics, Inc. LVTX
LAVA Therapeutics N.V. KZR
Kezar Life Sciences, Inc. FGEN
FibroGen, Inc. SKYE
Skye Bioscience, Inc. TVRD
Tvardi Therapeutics, Inc.

Résultat net

EBITDA

P/E Ratio

Capitalisation

Performance

Periode XLO PDSB ATNM TPST OKUR LVTX KZR FGEN SKYE TVRD
6M -5.59 % -45.91 % 6.00 % -56.05 % 31.22 % 32.82 % 39.82 % 44.70 % -53.71 % -84.90 %
YTD -39.25 % -49.35 % 26.19 % -73.30 % -63.50 % 68.93 % -3.81 % -37.11 % -64.92 % -20.61 %
1Y -30.70 % -49.93 % 41.96 % -68.16 % -61.37 % 75.95 % -3.07 % -5.88 % -65.04 % -20.61 %
3Y -68.60 % -90.35 % -84.41 % -82.63 % -86.77 % -53.97 % -99.04 % -97.66 % -69.23 % -20.61 %
5Y -95.94 % -60.70 % -85.79 % -91.17 % -97.93 % -87.83 % -98.80 % -99.17 % -91.11 % -20.61 %
10Y -95.94 % -99.64 % -97.96 % -99.87 % -97.93 % -87.83 % -99.64 % -98.89 % -99.43 % -20.61 %
Depuis le début -95.94 % -99.60 % -96.47 % -99.82 % -97.93 % -87.83 % -99.64 % -98.49 % -99.96 % -20.61 %

Dividende